Entity

Time filter

Source Type


Feng L.,Haicang Hospital of Xiamen | Chen Y.,Haicang Hospital of Xiamen | Gao Y.,Haicang Hospital of Xiamen | Fan X.,Haicang Hospital of Xiamen | And 2 more authors.
Cancer Research and Clinic | Year: 2015

Objective To study the clinical effects and side effects of recombinant human vascular endostatin combined with pemetrexed and cisplatin in the treatment of advanced lung adenocarcinoma. Methods Forty-seven patients with advanced lung adenocarcinoma were recruited from Jan 2011 to Jan 2013, and they were randomly divided into experimental group and control group. The experimental group (n = 24) was added with recombinant human vascular endostatin based on pemetrexed and cisplatin, whereas the control group (re = 23) was administered with pemetrexed and cisplatin only. The objective response rate (ORR), disease control rate (DCR), progressive disease (PD) rate, progression-free survival (PFS), overall survival (OS) and the side effects of 2 groups were evaluated. Results In the experimental group, ORR, DCR, PD rate, PFS and OS were 41.7 % (10/24), 79.2 % (19/24), 20.8 % (5/24), 8.0 months and 12.5 months respectively, while those of control group were 34.7 % (8/23), 47.8 % (11/23), 52.2 % (12/23), 6.2 months and 10.0 months. DCR, PD rate and PFS of experimental group had significant differences compared with control group (P < 0.05). OS of experimental group had no significant difference compared with control group (P > 0.05). The side effects of 2 groups were mainly hematologic toxicities, digestive reactions and fatigue, and the incidence rates were not significantly different between 2 groups (P > 0.05). Conclusions Recombinant human vascular endostatin combined with pemetrexed and cisplatin in treatment of patients with advanced lung adenocarcinoma improves the DCR, decreases the PD rate, prolongs the PFS. There is an increasing trend in the OS of experimental group, and with tolerable side effects. Source

Discover hidden collaborations